Scancell in-licenses Vaccitech technology to advance Modi-2 towards the clinic To download click here Monday 7 November 2022 09:54 Categories: Modi-2 Moditope News Regulatory News Year - 2022
Scancell in vanguard of immuno-oncology advances, with two technologies that show early promise The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise [View article] Tuesday 12 February 2019 20:07 Categories: Immunobody Media Coverage Modi-1 Modi-2 SCIB1 SCIB2 Year - 2019
Scancell lauds another six months of progress The funds raised in the last year "will allow us to focus on initiating the planned Phase 2 clinical trial for our lead ImmunoBody, SCIB1, and to advance our Moditope products, Modi-1 and Modi-2, towards the clinic". [View article] Thursday 31 January 2019 13:41 Categories: Immunobody Media Coverage Modi-1 Modi-2 Moditope SCIB1 Year - 2019
Scancell’s Modi-2 anti-cancer vaccine shows potential in pre-clinical studies Modi-2 is the second vaccine developed from the Moditope platform after Modi-1, and Scancell thinks each one has the potential to treat different types of cancer. [View article] Tuesday 30 October 2018 18:05 Categories: Media Coverage Modi-2 Year - 2018
Modi-2 : Extension of Moditope Platform To download click here To download related poster click here Tuesday 30 October 2018 12:00 Categories: Modi-2 Moditope News Regulatory News Year - 2018